381 related articles for article (PubMed ID: 29566768)
1. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
2. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
[TBL] [Abstract][Full Text] [Related]
3. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.
Vizeacoumar FJ; Arnold R; Vizeacoumar FS; Chandrashekhar M; Buzina A; Young JT; Kwan JH; Sayad A; Mero P; Lawo S; Tanaka H; Brown KR; Baryshnikova A; Mak AB; Fedyshyn Y; Wang Y; Brito GC; Kasimer D; Makhnevych T; Ketela T; Datti A; Babu M; Emili A; Pelletier L; Wrana J; Wainberg Z; Kim PM; Rottapel R; O'Brien CA; Andrews B; Boone C; Moffat J
Mol Syst Biol; 2013 Oct; 9():696. PubMed ID: 24104479
[TBL] [Abstract][Full Text] [Related]
4. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
5. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
6. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
Banerjee S; Buhrlage SJ; Huang HT; Deng X; Zhou W; Wang J; Traynor R; Prescott AR; Alessi DR; Gray NS
Biochem J; 2014 Jan; 457(1):215-25. PubMed ID: 24171924
[TBL] [Abstract][Full Text] [Related]
7. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
9. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
[TBL] [Abstract][Full Text] [Related]
11. Functional viability profiles of breast cancer.
Brough R; Frankum JR; Sims D; Mackay A; Mendes-Pereira AM; Bajrami I; Costa-Cabral S; Rafiq R; Ahmad AS; Cerone MA; Natrajan R; Sharpe R; Shiu KK; Wetterskog D; Dedes KJ; Lambros MB; Rawjee T; Linardopoulos S; Reis-Filho JS; Turner NC; Lord CJ; Ashworth A
Cancer Discov; 2011 Aug; 1(3):260-73. PubMed ID: 21984977
[TBL] [Abstract][Full Text] [Related]
12. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
Srihari S; Singla J; Wong L; Ragan MA
Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.
Mereniuk TR; El Gendy MA; Mendes-Pereira AM; Lord CJ; Ghosh S; Foley E; Ashworth A; Weinfeld M
Mol Cancer Ther; 2013 Oct; 12(10):2135-44. PubMed ID: 23883586
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy.
Ning L; Guo-Chun Z; Sheng-Li A; Xue-Rui L; Kun W; Jian Z; Chong-Yang R; Ling-Zhu W; Hai-Tong L
Tumour Biol; 2016 Apr; 37(4):5445-54. PubMed ID: 26563373
[TBL] [Abstract][Full Text] [Related]
16. Stromal PTEN determines mammary epithelial response to radiotherapy.
Sizemore GM; Balakrishnan S; Thies KA; Hammer AM; Sizemore ST; Trimboli AJ; Cuitiño MC; Steck SA; Tozbikian G; Kladney RD; Shinde N; Das M; Park D; Majumder S; Krishnan S; Yu L; Fernandez SA; Chakravarti A; Shields PG; White JR; Yee LD; Rosol TJ; Ludwig T; Park M; Leone G; Ostrowski MC
Nat Commun; 2018 Jul; 9(1):2783. PubMed ID: 30018330
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA‑142‑5p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog.
Xu W; Wang W
Mol Med Rep; 2018 Jun; 17(6):7529-7536. PubMed ID: 29620260
[TBL] [Abstract][Full Text] [Related]
18. Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.
Nakanishi Y; Walter K; Spoerke JM; O'Brien C; Huw LY; Hampton GM; Lackner MR
Cancer Res; 2016 Mar; 76(5):1193-203. PubMed ID: 26759240
[TBL] [Abstract][Full Text] [Related]
19. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
20. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.
Zhou XJ; Wu J; Shi L; Li XX; Zhu L; Sun X; Qian JY; Wang Y; Wei JF; Ding Q
J Exp Clin Cancer Res; 2017 Oct; 36(1):149. PubMed ID: 29052531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
